Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. AB Science
  6. News
  7. Summary
    AB   FR0010557264

AB SCIENCE

(AB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensus 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

AB Science Gets US FDA Nod to Start Study of Blood Cancer Drug

11/23/2021 | 12:13am EST


© MT Newswires 2021
All news about AB SCIENCE
01/19AB Science Gets French Nod to Start Phase 2 Study of Mast Cell Activation Syndrome Drug
MT
01/19AB Science has been granted authorization to initiate Phase II study in patients with s..
AQ
01/19AB Science SA Receives Authorization to Initiate Phase II Study in Patients with Severe..
CI
01/03AB Science Wins French Regulatory Nod To Launch Late-Stage Multiple Sclerosis Treatment..
MT
01/03AB Science granted authorization to initiate confirmatory Phase III trial of masitinib ..
AQ
01/03AB Science Announces That It Has Been Granted Authorization to Initiate Confirmatory Ph..
CI
2021GLOBAL MARKETS LIVE : Amazon, Microsoft, Volvo, Glencore, Regeneron...
2021AB Science Doses First Patient In COVID-19 Drug Trial
MT
2021AB Science announces dosing of first patient in Phase 2 trial of masitinib's antiviral ..
GL
2021AB Science S.A. Announces Dosing of First Patient in Phase 2 Trial of Masitinib?s Antiv..
CI
More news
Financials
Sales 2020 1,58 M 1,79 M 1,79 M
Net income 2020 -15,0 M -17,0 M -17,0 M
Net cash 2020 0,76 M 0,86 M 0,86 M
P/E ratio 2020 -57,8x
Yield 2020 -
Capitalization 511 M 579 M 577 M
EV / Sales 2019 156x
EV / Sales 2020 565x
Nbr of Employees 96
Free-Float 53,2%
Chart AB SCIENCE
Duration : Period :
AB Science Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AB SCIENCE
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 10,90 
Average target price
Spread / Average Target -
Managers and Directors
Alain Moussy Chairman & Chief Executive Officer
Laurent Guy Chief Financial Officer
Christian Fassotte Global Chief Medical Officer
Antonello Cervone Director-IT & Data Management
Véronique Gélébart Head-Clinical Operations & Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
AB SCIENCE-9.17%575
MERCK KGAA-16.30%93 755
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-11.47%37 178
KYOWA KIRIN CO. LTD.-9.44%13 352
SK BIOPHARMACEUTICALS CO., LTD.-11.52%5 612
BETTA PHARMACEUTICALS CO., LTD.-10.94%4 893